|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM013656872 |
| 003 |
DE-627 |
| 005 |
20250124135336.0 |
| 007 |
tu |
| 008 |
231221s1992 xx ||||| 00| ||jpn c |
| 028 |
5 |
2 |
|a pubmed25n0046.xml
|
| 035 |
|
|
|a (DE-627)NLM013656872
|
| 035 |
|
|
|a (NLM)1384295
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a jpn
|
| 100 |
1 |
|
|a Tsuji, Y
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Antiandrogen therapy of benign prostatic hypertrophy
|b clinical effects of allylestrenol evaluated by transrectal ultrasonographic measurement
|
| 264 |
|
1 |
|c 1992
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 03.11.1992
|
| 500 |
|
|
|a Date Revised 23.11.2016
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a A multicenter trial was carried out on 100 patients with benign prostatic hypertrophy to elucidate the efficacy of anti-androgen therapy with allylestrenol (AE). AE was administered at a daily dose of 50 mg for 16 weeks to the patients and its efficacy was evaluated with subjective symptom scores, residual urine volume and uroflow rates. The effects of AE on prostatic volume and morphology were evaluated using transrectal ultrasound. Of these patients 65 completed the protocol, and only three patients withdrew from the study owing to side effects. Very modest adverse effects on sexual performance were seen in one patient. In this study, significant beneficial effects of AE on symptom scores, residual urine, maximum flow rate, and prostate size were demonstrated. However, volumetric reduction was not associated with urodynamic improvement. Prostatic shape was not changed throughout the study. These findings suggest that allylestrenol can be used as an alternative to prostatectomy in patients who are at high risk for surgery
|
| 650 |
|
4 |
|a Clinical Trial
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Multicenter Study
|
| 650 |
|
7 |
|a Androgen Antagonists
|2 NLM
|
| 650 |
|
7 |
|a Allylestrenol
|2 NLM
|
| 650 |
|
7 |
|a I47VB5DZ8O
|2 NLM
|
| 700 |
1 |
|
|a Ariyoshi, A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Nakamura, H
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Michinaga, S
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tomita, Y
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ohmori, A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tahara, H
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yamashita, Y
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Fujisawa, Y
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kajiwara, I
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Hinyokika kiyo. Acta urologica Japonica
|d 1962
|g 38(1992), 8 vom: 10. Aug., Seite 961-6
|w (DE-627)NLM012631779
|x 0018-1994
|7 nnns
|
| 773 |
1 |
8 |
|g volume:38
|g year:1992
|g number:8
|g day:10
|g month:08
|g pages:961-6
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2003
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2010
|
| 912 |
|
|
|a GBV_ILN_2012
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 38
|j 1992
|e 8
|b 10
|c 08
|h 961-6
|